Report cover image

Rheumatology Therapeutics Market by Indication (Ankylosing Spondylitis, Gout, Osteoarthritis), Distribution Channel (Offline Mode, Online Stores) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 184 Pages
SKU # IRE18449709

Description

Rheumatology Therapeutics Market by Indication (Ankylosing Spondylitis, Gout, Osteoarthritis), Distribution Channel (Offline Mode, Online Stores) - Global Forecast 2024-2030


The Rheumatology Therapeutics Market size was estimated at USD 31.23 billion in 2023 and expected to reach USD 33.24 billion in 2024, at a CAGR 6.51% to reach USD 48.58 billion by 2030.

Global Rheumatology Therapeutics Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Rheumatology Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Rheumatology Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Rheumatology Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Amgen, Inc., AstraZeneca Plc, Bayer AG, Beckman Coulter, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Qiagen NV, Regeneron Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Sanofi SA, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage



This research report categorizes the Rheumatology Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Indication
Ankylosing Spondylitis
Gout
Osteoarthritis
Psoriatic Arthritis
Rheumatoid Arthritis
Distribution Channel
Offline Mode
Online Stores
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Rheumatology Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Rheumatology Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Rheumatology Therapeutics Market?
4. What is the market share of the leading vendors in the Rheumatology Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Rheumatology Therapeutics Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

184 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Rheumatology Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing incidence of rheumatoid arthritis globally coupled with increasing geriatric population
5.1.1.2. Availability of favorable reimbursement policies
5.1.1.3. Increasing launch of novel therapeutic agents
5.1.2. Restraints
5.1.2.1. High cost of RA therapeutics
5.1.3. Opportunities
5.1.3.1. Developments and improvements in diagnostics and healthcare infrastructure
5.1.3.2. Widespread awareness on arthritis and its prevention among patients
5.1.4. Challenges
5.1.4.1. Probable impact on lining of stomach, kidney damage, and heart issues
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Rheumatology Therapeutics Market, by Indication
6.1. Introduction
6.2. Ankylosing Spondylitis
6.3. Gout
6.4. Osteoarthritis
6.5. Psoriatic Arthritis
6.6. Rheumatoid Arthritis
7. Rheumatology Therapeutics Market, by Distribution Channel
7.1. Introduction
7.2. Offline Mode
7.3. Online Stores
8. Americas Rheumatology Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Rheumatology Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Rheumatology Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie, Inc.
12.1.2. Amgen, Inc.
12.1.3. AstraZeneca Plc
12.1.4. Bayer AG
12.1.5. Beckman Coulter, Inc.
12.1.6. Boehringer Ingelheim GmbH
12.1.7. Bristol-Myers Squibb Company
12.1.8. Eli Lilly and Company
12.1.9. F. Hoffmann-La Roche AG
12.1.10. Gilead Sciences, Inc.
12.1.11. Johnson & Johnson Services, Inc.
12.1.12. Merck & Co., Inc.
12.1.13. Novartis International AG
12.1.14. Pfizer, Inc.
12.1.15. Qiagen NV
12.1.16. Regeneron Pharmaceuticals, Inc.
12.1.17. Rigel Pharmaceuticals, Inc.
12.1.18. Sanofi SA
12.1.19. Thermo Fisher Scientific, Inc.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. RHEUMATOLOGY THERAPEUTICS MARKET DYNAMICS
FIGURE 7. RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 8. RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us